These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37721425)

  • 1. Enhanced Photoacoustic Imaging of Urokinase-Type Plasminogen Activator Activity in Tumors.
    Hu X; Sun X; Liu X; Xu HD; Yang L; Liu S; Wang R; Liang G
    Anal Chem; 2023 Oct; 95(39):14511-14515. PubMed ID: 37721425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioluminescence Imaging of Urokinase-Type Plasminogen Activator Activity
    Chen Y; Wu C; Wang C; Zhang T; Hua Y; Shen Y; Liang G
    Anal Chem; 2021 Jul; 93(29):9970-9973. PubMed ID: 34264075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Activatable Polymeric Reporter for Near-Infrared Fluorescent and Photoacoustic Imaging of Invasive Cancer.
    Li Q; Li S; He S; Chen W; Cheng P; Zhang Y; Miao Q; Pu K
    Angew Chem Int Ed Engl; 2020 Apr; 59(18):7018-7023. PubMed ID: 32124526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alkaline Phosphatase-Triggered Self-Assembly of Near-Infrared Nanoparticles for the Enhanced Photoacoustic Imaging of Tumors.
    Wu C; Zhang R; Du W; Cheng L; Liang G
    Nano Lett; 2018 Dec; 18(12):7749-7754. PubMed ID: 30481463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
    Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
    Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
    Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
    Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
    Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
    Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
    Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
    Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C; Yu J; Huang S
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease.
    Qin W; Zhu W; Wagner-Mann C; Sauter ER
    Ann Surg Oncol; 2003 Oct; 10(8):948-53. PubMed ID: 14527916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase-type plasminogen activator promotes paracellular transmigration of neutrophils via Mac-1, but independently of urokinase-type plasminogen activator receptor.
    Reichel CA; Uhl B; Lerchenberger M; Puhr-Westerheide D; Rehberg M; Liebl J; Khandoga A; Schmalix W; Zahler S; Deindl E; Lorenzl S; Declerck PJ; Kanse S; Krombach F
    Circulation; 2011 Oct; 124(17):1848-59. PubMed ID: 21969013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
    Duggan C; Maguire T; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
    Int J Cancer; 1995 May; 61(5):597-600. PubMed ID: 7768629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
    Stillfried GE; Saunders DN; Ranson M
    Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis.
    Humphries J; Gossage JA; Modarai B; Burnand KG; Sisson TH; Murdoch C; Smith A
    J Vasc Surg; 2009 Nov; 50(5):1127-34. PubMed ID: 19703758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
    Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
    Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
    Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
    Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
    Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion.
    Okada SS; Grobmyer SR; Barnathan ES
    Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1269-76. PubMed ID: 8857924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.